Analyst Commentary on Stryker’s ASC Robotics Position
On 12 June 2026, BTIG analyst Ryan Zimmerman issued a Buy rating on Stryker Corp (NYSE:SYK) with a revised price target of $379 per share. The rating was underpinned by the performance of Stryker’s Mako robotic system, which he described as a leading platform for ambulatory surgery centers (ASCs) following a shift from discretionary to essential use, a trend highlighted at the Becker’s Healthcare Spine, Orthopedic, and Pain Management‑Driven ASC conference in Chicago.
Zimmerman also maintained Buy ratings on three peer companies: Medtronic Inc (NYSE:MDT) with a $90 target, Boston Scientific Corp (NYSE:BSX) at $65, and Solventum Ltd (NYSE:SOLV) at $89. Neutral ratings were retained on Zimmer Biomet Holdings Inc (NYSE:ZBH) and Globus Medical Inc (NASDAQ:GMED).
The article notes that flexible contract structures—such as volume‑based agreements and walk‑away clauses—have lowered financial risk for ASCs, facilitating broader adoption of robotic platforms. Younger surgeons increasingly regard robotic systems as a baseline requirement, while patients actively seek robotic‑assisted procedures, turning robotics into both a competitive necessity and a marketing advantage for ASC operators.
A significant challenge identified is the current reimbursement environment, described by a spine surgeon at the conference as the most difficult in the past 25 years. Insurers are outsourcing adjudication to third‑party contractors, which has compressed margins and heightened demand for AI‑driven coding and billing solutions. Medicare has introduced coverage cuts to nerve‑block usage in certain procedures, prompting providers to diversify into neuromodulation technologies, including spinal‑cord stimulation, peripheral nerve stimulation, deep‑brain stimulation, sleep‑apnea devices, and pelvic‑health devices.
Augmented reality (AR) was cited as the preferred cost‑effective enabling technology for spine and orthopedics ASCs, whereas robotics faces economic headwinds due to high acquisition costs and limited incremental reimbursement. Key innovation catalysts identified include advances in AR that reduce reliance on pre‑operative imaging, the expiration of BMP/Infuse patents opening the biologics market, and growing momentum in total disc replacement procedures.
The article was generated with AI assistance and reviewed by an editor, with standard Reuters terms and conditions applying.